CIK 0001162194 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2021 | FY2020 | |
|---|---|---|---|---|
| Revenue (USD) | 85.3 M | 97.9 M | ||
| Net income (USD) | -53.0 M | -59.0 M | ||
| Diluted EPS (USD/shares) | -0.2 | -2.43 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-21 | S-4/A | S-4/A | |
| 2026-10-09 | S-4/A | S-4/A | |
| 2026-10-05 | 425 | 425 | |
| 2026-10-05 | 8-K | 8-K items 7.01,9.01 | 2026-10-05 |
| 2026-09-30 | 425 | 425 | |
| 2026-09-30 | 8-K | 8-K items 1.01,1.02,7.01,9.01 | 2026-09-30 |
| 2026-09-09 | S-4/A | S-4/A | |
| 2026-08-24 | 4 | 4 | 2026-08-20 |
| 2026-08-24 | 4 | 4 | 2026-08-20 |
| 2026-08-24 | 4 | 4 | 2026-08-20 |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-14 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-08-05 | S-8 | FORM S-8 | |
| 2026-08-05 | S-8 | FORM S-8 | |
| 2026-08-05 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-05 | 8-K | 8-K items 2.02,7.01,9.01 | 2026-08-05 |
| 2026-08-04 | 4 | 4 | 2026-08-03 |
| 2026-07-30 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-07-29 | 425 | 425 | |
| 2026-07-29 | 8-K/A | 8-K/A items 9.01 | 2026-07-28 |
| 2026-07-28 | 425 | 425 | |
| 2026-07-28 | 425 | 425 | |
| 2026-07-28 | 8-K | 8-K items 1.01,7.01,9.01 | 2026-07-24 |
| 2026-07-27 | 4 | 4 | 2026-07-23 |
| 2026-07-24 | 8-K | 8-K items 3.01 | 2026-07-22 |
Forms on file (last 1,000): 4 498, 8-K 146, SC 13G/A 47, 10-Q 31, 3 29, DEFA14A 24, 144 22, SC 13D/A 22. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=LAB (0.002 USD), /gw/filings/filings?ticker=LAB&form=8-K, /gw/filings/facts?ticker=LAB&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange